<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LANOXIN- digoxinÂ injection, solutionÂ </strong><br>Covis Pharmaceuticals Inc<br></p></div>
<h1>LANOXIN<span class="Sup">Â®</span><br>(digoxin) <br>Injection Pediatric<br>100Â mcg (0.1Â mg) in 1Â mL</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c7ad4c03-1ba0-4684-bdd7-a94edc40af38"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">LANOXIN (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of <span class="Italics">Digitalis lanata.</span>The term â€œdigitalisâ€? is used to designate the whole group of glycosides. The glycosides are composed of 2 portions: a sugar and a cardenolide (henceâ€œglycosidesâ€?).</p>
<p>Digoxin is described chemically as (3Î²,5Î²,12Î²)-3-[(<span class="Italics">O</span>-2,6-dideoxy-Î²-<span class="Italics">D-ribo</span>-hexopyranosyl-(1â†’4)-<span class="Italics">O</span>-2,6-dideoxy-Î²-<span class="Italics">D</span>-<span class="Italics">ribo</span>-hexopyranosyl-(1â†’4)-2,6-dideoxy-Î²-<span class="Italics">D</span>-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide. Its molecular formula is C<span class="Sub">41</span>H<span class="Sub">64</span>O<span class="Sub">14</span>, its molecular weight is 780.95, and its structural formula is:</p>
<div class="Figure"><img alt="Digoxin Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=58678fd6-afe3-4a4c-a37f-356444194cd6&amp;name=5de543bc-1234-4760-b78b-b8f0258aa45c-01.jpg"></div>
<p>Digoxin exists as odorless white crystals that melt with decomposition above 230Â°C. The drug is practically insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in chloroform; and freely soluble in pyridine.</p>
<p>LANOXIN Injection Pediatric is a sterile solution of digoxin for intravenous or intramuscular injection. The vehicle contains 40% propylene glycol and 10% alcohol. The injection is buffered to a pH of 6.8 to 7.2 with 0.17% sodium phosphate and 0.08% anhydrous citric acid. Each 1-mL ampul contains 100Â mcg (0.1Â mg) digoxin. Dilution is not required.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7cc9055e-985e-49b0-a52a-2b480c706115"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_fcec2951-f2f5-499e-b55b-588a404c13ca"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Digoxin inhibits sodium-potassium ATPase, an enzyme that regulates the quantity of sodium and potassium inside cells. Inhibition of the enzyme leads to an increase in the intracellular concentration of sodium and thus (by stimulation of sodium-calcium exchange) an increase in the intracellular concentration of calcium. The beneficial effects of digoxin result from direct actions on cardiac muscle, as well as indirect actions on the cardiovascular system mediated by effects on the autonomic nervous system. The autonomic effects include: (1)Â a vagomimetic action, which is responsible for the effects of digoxin on the sinoatrial and atrioventricular (AV) nodes; and (2)Â baroreceptor sensitization, which results in increased afferent inhibitory activity and reduced activity of the sympathetic nervous system and renin-angiotensin system for any given increment in mean arterial pressure. The pharmacologic consequences of these direct and indirect effects are: (1)Â an increase in the force and velocity of myocardial systolic contraction (positive inotropic action); (2)Â a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect); and (3)Â slowing of the heart rate and decreased conduction velocity through the AV node (vagomimetic effect). The effects of digoxin in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> are mediated by its positive inotropic and neurohormonal deactivating effects, whereas the effects of the drug in <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span> are related to its vagomimetic actions. In high doses, digoxin increases sympathetic outflow from the central nervous system (CNS). This increase in sympathetic activity may be an important factor in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_6b27300a-9835-459c-8064-660c2bd88c68"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Note: The following data are from studies performed in adults, unless otherwise stated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_85caee48-b4b4-4cf2-8f1f-e08cf1641f9a"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Absorption</span></span></h3>
<p class="First">Comparisons of the systemic availability and equivalent doses for preparations of digoxin are shown in Table 1.</p>
<a name="id_4b4ca07e-fd8e-406f-97e9-de3895c5037c"></a><table width="0.000">
<caption><span>Table 1. Comparisons of the Systemic Availability and Equivalent Doses for Preparations of LANOXIN</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Product</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Absolute Bioavailability</p></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top">
<p class="First">Equivalent Doses (mcg)<span class="Sup">a</span></p>
<p>Among Dosage Forms</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">LANOXIN Tablets</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">60 - 80%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">62.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">125</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">250</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">500</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">LANOXIN Injection/IV</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">100%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">50</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">100</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">200</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">400</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> For example, 125-mcg LANOXIN Tablets equivalent to 100Â mcg LANOXIN Injection/IV.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa98ba8c-2b73-4222-9e44-a16c04ea40e5"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Distribution</span></span></h3>
<p class="First">Following drug administration, a 6- to 8-hour tissue distribution phase is observed. This is followed by a much more gradual decline in the serum concentration of the drug, which is dependent on the elimination of digoxin from the body. The peak height and slope of the early portion (absorption/distribution phases) of the serum concentration-time curve are dependent upon the route of administration and the absorption characteristics of the formulation. Clinical evidence indicates that the early high serum concentrations do not reflect the concentration of digoxin at its site of action, but that with chronic use, the steady-state post-distribution serum concentrations are in equilibrium with tissue concentrations and correlate with pharmacologic effects. In individual patients, these post-distribution serum concentrations may be useful in evaluating therapeutic and toxic effects (see DOSAGE AND ADMINISTRATION: Serum Digoxin Concentrations).</p>
<p>Digoxin is concentrated in tissues and therefore has a large apparent volume of distribution. Digoxin crosses both the blood-brain barrier and the placenta. At delivery, the serum digoxin concentration in the newborn is similar to the serum concentration in the mother. Approximately 25% of digoxin in the plasma is bound to protein. Serum digoxin concentrations are not significantly altered by large changes in fat tissue weight, so that its distribution space correlates best with lean (i.e., ideal) body weight, not total body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cabecc44-caea-43a3-afff-0299b8c20d95"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Italics"><span class="Bold">Metabolism</span></span></h3>
<p class="First">Only a small percentage (16%) of a dose of digoxin is metabolized. The end metabolites, which include 3 Î²-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation. The metabolism of digoxin is not dependent upon the cytochrome P-450 system, and digoxin is not known to induce or inhibit the cytochrome P-450 system.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbd4aae2-c598-47ce-be31-2351b12daf43"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Italics"><span class="Bold">Excretion</span></span></h3>
<p class="First">Elimination of digoxin follows first-order kinetics (that is, the quantity of digoxin eliminated at any time is proportional to the total body content). Following intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine. Renal excretion of digoxin is proportional to glomerular filtration rate and is largely independent of urine flow. In healthy volunteers with normal renal function, digoxin has a half-life of 1.5 to 2.0Â days. The half-life in anuric patients is prolonged to 3.5 to 5Â days. Digoxin is not effectively removed from the body by dialysis, exchange transfusion, or during cardiopulmonary bypass because most of the drug is bound to tissue and does not circulate in the blood.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f545093d-ec50-458b-9fdd-07bd6ce11184"></a><a name="section-2.2.5"></a><p></p>
<h3><span class="Italics"><span class="Bold">Special Populations</span></span></h3>
<p class="First">Race differences in digoxin pharmacokinetics have not been formally studied. Because digoxin is primarily eliminated as unchanged drug via the kidney and because there are no important differences in creatinine clearance among races, pharmacokinetic differences due to race are not expected.</p>
<p>The clearance of digoxin can be primarily correlated with renal function as indicated by creatinine clearance. In children with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, digoxin must be carefully titrated based upon clinical response.</p>
<p>Plasma digoxin concentration profiles in patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> generally fell within the range of profiles in a group of healthy subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_077a40a2-7ec7-4e2d-9b1f-daf1e1b1ec65"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacodynamic and Clinical Effects</h2>
<p class="First">The times to onset of pharmacologic effect and to peak effect of preparations of LANOXIN are shown in TableÂ 2.</p>
<a name="id_aa52bc91-015c-4b56-a36c-cae0bde1ff39"></a><table width="0.000">
<caption><span>Table 2. Times to Onset of Pharmacologic Effect and to Peak Effect of Preparations of LANOXIN</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Product</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Time to Onset of Effect<span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Time to Peak Effect<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">LANOXIN Tablets</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.5 - 2 hours</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 - 6 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">LANOXIN Injection/IV</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5 - 30 minutes<span class="Sup">b</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 - 4 hours</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Documented for ventricular response rate in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, inotropic effects and electrocardiographic changes.</p>
<p><span class="Sup">b</span> Depending upon rate of infusion.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5870eeb2-9eb5-41d3-89b9-2cb24d3a5fcf"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Hemodynamic Effects</span></span></h3>
<p class="First">Digoxin produces hemodynamic improvement in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Short- and long-term therapy with the drug increases <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and lowers pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>. These hemodynamic effects are accompanied by an increase in the left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and a decrease in end-systolic and end-diastolic dimensions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74201ad1-b52f-4cfa-9bef-b3e0b4f643bb"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></span></h3>
<p class="First">Two 12-week, double-blind, placebo-controlled studies enrolled 178Â (RADIANCE trial) and 88Â (PROVED trial) adult patients with NYHA class II or III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> previously treated with oral digoxin, a diuretic, and an ACE inhibitor (RADIANCE only) and randomized them to placebo or treatment with LANOXIN Tablets. Both trials demonstrated better preservation of exercise capacity in patients randomized to LANOXIN. Continued treatment with LANOXIN reduced the risk of developing worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, as evidenced by <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>-related hospitalizations and emergency care and the need for concomitant <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> therapy. The larger study also showed treatment-related benefits in NYHA class and patientsâ€™ global assessment. In the smaller trial, these trended in favor of a treatment benefit.</p>
<p>The Digitalis Investigation Group (DIG) main trial was a multicenter, randomized, double-blind, placebo-controlled mortality study of 6,801Â adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤0.45. At randomization, 67% were NYHA class I or II, 71% had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of ischemic etiology, 44% had been receiving digoxin, and most were receiving concomitant ACE inhibitor (94%) and diuretic (82%). Patients were randomized to placebo or LANOXIN Tablets, the dose of which was adjusted for the patientâ€™s age, sex, lean body weight, and serum creatinine (see DOSAGE AND ADMINISTRATION), and followed for up to 58Â months (median 37Â months). The median daily dose prescribed was 0.25Â mg. Overall all-cause mortality was 35% with no difference between groups (95% confidence limits for relative risk of 0.91 to 1.07). LANOXIN was associated with a 25% reduction in the number of hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, a 28% reduction in the risk of a patient having at least 1 hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and a 6.5% reduction in total hospitalizations (for any cause).</p>
<p>Use of LANOXIN was associated with a trend to increase time to all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization. The trend was evident in subgroups of patients with mild <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> as well as more severe disease, as shown in TableÂ 3. Although the effect on all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization was not statistically significant, much of the apparent benefit derived from effects on mortality and hospitalization attributed to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<a name="id_73cc2fbc-b066-4fa8-bd9f-6e4ebee820e3"></a><table width="0.000">
<caption><span>Table 3. Subgroup Analyses of Mortality and Hospitalization During the First 2 Years Following Randomization</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First">n</p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><p class="First">Risk of All-Cause Mortality or All-Cause Hospitalization<span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><p class="First">Risk of HF-Related Mortality or HF-Related Hospitalization<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">LANOXIN</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Relative risk<span class="Sup">b</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">LANOXIN</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Relative risk<span class="Sup">b</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">All patients (EF â‰¤0.45)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6,801</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">604</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">593</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.94 </p>
<p>(0.88-1.00)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">294</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">217</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.69</p>
<p>(0.63-0.76)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">NYHA I/II</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4,571</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">549</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">541</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.96 </p>
<p>(0.89-1.04)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">242</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">178</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.70</p>
<p>(0.62-0.80)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">EF 0.25-0.45</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4,543</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">568</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">571</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.99</p>
<p>(0.91-1.07)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">244</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">190</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.74</p>
<p>(0.66-0.84)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">CTR â‰¤0.55</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4,455</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">561</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">563</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.98</p>
<p>(0.91-1.06)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">239</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">180</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.71</p>
<p>(0.63-0.81)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">NYHA III/IV</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2,224</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">719</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">696</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.88</p>
<p>(0.80-0.97)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">402</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">295</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.65</p>
<p>(0.57-0.75)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">EF &lt;0.25</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2,258</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">677</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">637</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.84</p>
<p>(0.76-0.93)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">394</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">270</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.61</p>
<p>(0.53-0.71)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">CTR &gt;0.55</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2,346</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">687</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">650</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.85</p>
<p>(0.77-0.94)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">398</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">287</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.65</p>
<p>(0.57-0.75)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">EF &gt;0.45<span class="Sup">c</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">987</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">571</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">585</p></td>
<td class="Rrule" align="center" valign="top">
<p class="First">1.04</p>
<p>(0.88-1.23)</p>
</td>
<td class="Rrule" align="center" valign="top"><p class="First">179</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">136</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.72</p>
<p>(0.53-0.99)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Number of patients with an event during the first 2Â years per 1,000Â randomized patients.</p>
<p><span class="Sup">b</span> Relative risk (95% confidence interval). </p>
<p><span class="Sup">c</span> DIG Ancillary Study.</p>
<p>In situations where there is no statistically significant benefit of treatment evident from a trialâ€™s primary endpoint, results pertaining to a secondary endpoint should be interpreted cautiously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff6d8f42-a7de-4fb1-96f5-ce7860d27e0e"></a><a name="section-2.3.3"></a><p></p>
<h3><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Chronic Atrial Fibrillation</span></span></span></h3>
<p class="First">In adult patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span>, digoxin slows rapid ventricular response rate in a linear dose-response fashion from 0.25 to 0.75Â mg/day. Digoxin should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">multifocal atrial tachycardia</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4819f09f-432e-4557-bc5f-7db44ff80eff"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e28a1719-417e-4d6f-ade7-a97bec86d7b7"></a><a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">LANOXIN is indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. LANOXIN increases left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and improves <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> symptoms as evidenced by exercise capacity and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these 3 drugs cannot be specified.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1270aa90-63f3-41cc-b0f2-9b450b4500c7"></a><a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First">LANOXIN is indicated for the control of ventricular response rate in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0f4a6cba-f298-4d9f-a16c-671821cdccd4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Digitalis glycosides are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> or in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to digoxin. A <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to other digitalis preparations usually constitutes a contraindication to digoxin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e9df677f-d14b-43ce-9530-ff0307813638"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3fd03f7-cd4a-44c0-93f5-edbc5892b002"></a><a name="section-5.1"></a><p></p>
<h2>Sinus Node Disease and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span></h2>
<p class="First">Because digoxin slows sinoatrial and AV conduction, the drug commonly prolongs the PR interval. The drug may cause severe <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> or <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">sinoatrial block</span> in patients with pre-existing sinus node disease and may cause advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span> in patients with pre-existing incomplete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. In such patients consideration should be given to the insertion of a pacemaker before treatment with digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_16d98ffe-4a62-40e9-a3a9-f03ab5c41349"></a><a name="section-5.2"></a><p></p>
<h2>Accessory AV Pathway (Wolff-Parkinson-White Syndrome)</h2>
<p class="First">After intravenous digoxin therapy, some patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">paroxysmal atrial fibrillation</span> or flutter and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, leading to a very rapid ventricular response or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. Unless conduction down the accessory pathway has been blocked (either pharmacologically or by surgery), digoxin should not be used in such patients. The treatment of <span class="product-label-link" type="condition" conceptid="317893" conceptname="Paroxysmal supraventricular tachycardia">paroxysmal supraventricular tachycardia</span> in such patients is usually direct-current cardioversion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09df64b3-c3f9-4d11-bc85-708c93550a52"></a><a name="section-5.3"></a><p></p>
<h2>Use in Patients With Preserved Left Ventricular Systolic Function</h2>
<p class="First">Patients with certain disorders involving <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> associated with preserved left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> may be particularly susceptible to toxicity of the drug. Such disorders include <span class="product-label-link" type="condition" conceptid="4190773" conceptname="Restrictive cardiomyopathy">restrictive cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>, amyloid heart disease, and <span class="product-label-link" type="condition" conceptid="312927" conceptname="Acute cor pulmonale">acute cor pulmonale</span>. Patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">idiopathic hypertrophic subaortic stenosis</span> may have worsening of the outflow obstruction due to the inotropic effects of digoxin. Digoxin should generally be avoided in these patients, although it has been used for ventricular rate control in the subgroup of patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_285e5aa5-ee71-408a-a1cc-c0515832e9e9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c818429e-e815-4bed-8678-b5dfea93baf9"></a><a name="section-6.1"></a><p></p>
<h2>Use in Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Digoxin is primarily excreted by the kidneys; therefore, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> require smaller than usual maintenance doses of digoxin (see DOSAGE AND ADMINISTRATION). Because of the prolonged elimination half-life, a longer period of time is required to achieve an initial or new steady-state serum concentration in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> than in patients with normal renal function. If appropriate care is not taken to reduce the dose of digoxin, such patients are at high risk for toxicity, and toxic effects will last longer in such patients than in patients with normal renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91b5f7cc-a55d-4b5b-8d20-8fd5a1d4150c"></a><a name="section-6.2"></a><p></p>
<h2>Use in Patients With Electrolyte Disorders</h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, toxicity may occur despite serum digoxin concentrations below 2.0Â ng/mL, because potassium or magnesium depletion sensitizes the myocardium to digoxin. Therefore, it is desirable to maintain normal serum potassium and magnesium concentrations in patients being treated with digoxin. Deficiencies of these electrolytes may result from <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or prolonged <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, as well as the use of the following drugs or procedures: diuretics, amphotericinÂ B, corticosteroids, antacids, dialysis, and mechanical suction of gastrointestinal secretions.</p>
<p><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> from any cause predisposes the patient to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Calcium, particularly when administered rapidly by the intravenous route, may produce serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in digitalized patients. On the other hand, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> can nullify the effects of digoxin in humans; thus, digoxin may be ineffective until serum calcium is restored to normal. These interactions are related to the fact that digoxin affects contractility and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> of the heart in a manner similar to that of calcium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b689a4e7-b663-4b09-af3d-b84510519e14"></a><a name="section-6.3"></a><p></p>
<h2>Use in <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span> and Hypermetabolic States</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> may reduce the requirements for digoxin. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> and/or <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span> resulting from hypermetabolic or hyperdynamic states (e.g., <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, or arteriovenous shunt) are best treated by addressing the underlying condition. <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">Atrial arrhythmias</span> associated with hypermetabolic states are particularly resistant to digoxin treatment. Care must be taken to avoid toxicity if digoxin is used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ff7221b-ea04-4c2b-90b9-bb0fda2e3ce1"></a><a name="section-6.4"></a><p></p>
<h2>Use in Patients With <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></h2>
<p class="First">Digoxin should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>. The use of inotropic drugs in some patients in this setting may result in undesirable increases in myocardial oxygen demand and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_537976ae-077c-4409-b64a-3d0b6b67f0d3"></a><a name="section-6.5"></a><p></p>
<h2>Use During Electrical Cardioversion</h2>
<p class="First">It may be desirable to reduce the dose of digoxin for 1 to 2Â days prior to electrical cardioversion of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> to avoid the induction of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, but physicians must consider the consequences of increasing the ventricular response if digoxin is withdrawn. If <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> is suspected, elective cardioversion should be delayed. If it is not prudent to delay cardioversion, the lowest possible energy level should be selected to avoid provoking <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_609be5a7-0097-48db-83ec-f96d1b9d488d"></a><a name="section-6.6"></a><p></p>
<h2>Use in Patients With <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span></h2>
<p class="First">Digoxin can rarely precipitate <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and therefore should be avoided in patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3aeacea3-1d0e-426a-8704-624c832a1b34"></a><a name="section-6.7"></a><p></p>
<h2>Use in Patients With <span class="product-label-link" type="condition" conceptid="434620" conceptname="Beriberi">Beri Beri</span> Heart Disease</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="434620" conceptname="Beriberi">beri beri</span> heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_2d0ea4fd-2cb3-4ed0-94dc-08fde5fca124"></a><a name="section-6.8"></a><p></p>
<h2>Laboratory Test Monitoring</h2>
<p class="First">Patients receiving digoxin should have their serum electrolytes and renal function (serum creatinine concentrations) assessed periodically; the frequency of assessments will depend on the clinical setting. For discussion of serum digoxin concentrations, see DOSAGE AND ADMINISTRATION.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_2dfa619b-95d0-4415-a8ae-17b36861f7cd"></a><a name="section-6.9"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Potassium-depleting <span class="Italics">diuretics </span>are a major contributing factor to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. <span class="Italics">Calcium</span>, particularly if administered rapidly by the intravenous route, may produce serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in digitalized patients. <span class="Italics">Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam</span>,Â and<span class="Italics">spironolactone</span> raise the serum digoxin concentration due to a reduction in clearance and/or volume of distribution of the drug, with the implication that <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span> may result. <span class="Italics">Erythromycin</span> and <span class="Italics">clarithromycin</span> (and possibly other <span class="Italics">macrolide antibiotics</span>) and <span class="Italics">tetracycline</span> may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span> may result. <span class="Italics">Propantheline</span> and <span class="Italics">diphenoxylate,</span> by decreasing gut motility, may increase digoxin absorption. <span class="Italics">Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine</span>, certain <span class="Italics">anticancer drugs</span>,Â and <span class="Italics">metoclopramide</span> may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations. <span class="Italics">Rifampin</span> may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin. There have been inconsistent reports regarding the effects of other drugs (e.g., <span class="Italics">quinine</span>, <span class="Italics">penicillamine</span>) on serum digoxin concentration. <span class="Italics">Thyroid</span> administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin. Concomitant use of digoxin and <span class="Italics">sympathomimetics</span> increases the risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. <span class="Italics">Succinylcholine</span> may cause a sudden extrusion of potassium from muscle cells, and may thereby cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in digitalized patients. Although calcium channel blockers and digoxin may be useful in combination to control <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, their additive effects on AV node conduction can result in advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly. Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing carvedilol.</p>
<p>Due to the considerable variability of these interactions, dosage of digoxin should be individualized when patients receive these medications concurrently. Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_aba4a703-4604-4863-aed9-e03cba04bdeb"></a><a name="section-6.10"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">The use of therapeutic doses of digoxin may cause prolongation of the PR interval and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the ST segment on the electrocardiogram. Digoxin may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects reflect an expected effect of the drug and are not indicative of toxicity.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_09c225fb-5763-4dda-a6a7-45296048982c"></a><a name="section-6.11"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Digoxin showed no genotoxic potential in <span class="Italics">in vitro</span> studies (Ames test and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>). No data are available on the carcinogenic potential of digoxin, nor have studies been conducted to assess its potential to affect fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_f97f1473-b042-4d8e-b2fa-d117cdfe387c"></a><a name="section-6.12"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_64e29551-d6fd-4fbb-974f-7b9cc2f0cfaa"></a><a name="section-6.12.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Teratogenic Effects</span></span></h3>
<p class="First">Pregnancy CategoryÂ C. Animal reproduction studies have not been conducted with digoxin. It is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Digoxin should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4c693b13-fa7b-41c7-b85f-429739c29892"></a><a name="section-6.13"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Studies have shown that digoxin concentrations in the motherâ€™s serum and milk are similar. However, the estimated exposure of a nursing infant to digoxin via breastfeeding will be far below the usual infant maintenance dose. Therefore, this amount should have no pharmacologic effect upon the infant. Nevertheless, caution should be exercised when digoxin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_538d1e8b-411a-4c56-9ca7-f263abd51929"></a><a name="section-6.14"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Newborn infants display considerable variability in their tolerance to digoxin. Premature and immature infants are particularly sensitive to the effects of digoxin, and the dosage of the drug must not only be reduced but must be individualized according to their degree of maturity. Digitalis glycosides can cause <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> in children due to accidental ingestion.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_0b863a13-39a1-4df2-82dd-a9e68f6ee8f6"></a><a name="section-6.15"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">The majority of clinical experience gained with digoxin has been in the elderly population. This experience has not identified differences in response or adverse effects between the elderly and younger patients. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_fd1e5098-7ad4-4b96-92fe-d996d941cef3"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In general, the adverse reactions of digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when digoxin is used within the recommended dose range or therapeutic serum concentration range and when there is careful attention to concurrent medications and conditions.</p>
<p>Because some patients may be particularly susceptible to side effects with digoxin, the dosage of the drug should always be selected carefully and adjusted as the clinical condition of the patient warrants. In the past, when high doses of digoxin were used and little attention was paid to clinical status or concurrent medications, adverse reactions to digoxin were more frequent and severe. Cardiac adverse reactions accounted for about one-half, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse reactions. However, available evidence suggests that the incidence and severity of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> has decreased substantially in recent years. In recent controlled clinical trials, in patients with predominantly mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the incidence of adverse experiences was comparable in patients taking digoxin and in those taking placebo. In a large mortality trial, the incidence of hospitalization for suspected <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> was 2% in patients taking LANOXIN Tablets compared to 0.9% in patients taking placebo. In this trial, the most common manifestations of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> included gastrointestinal and cardiac disturbances; CNS manifestations were less common.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88a394aa-8da7-4a16-8e66-1b0bb0346033"></a><a name="section-7.1"></a><p></p>
<h2>Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da7b355b-8f14-4626-9d0c-32c2759991c5"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Cardiac</span></span></h3>
<p class="First">Therapeutic doses of digoxin may cause <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> in patients with pre-existing sinoatrial or AV conduction disorders; <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> can be avoided by adjusting the dose of digoxin. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> use of a cardiac pacemaker may be considered if the risk of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> is considered unacceptable. High doses of digoxin may produce a variety of rhythm disturbances, such as first-degree, second-degree (<span class="product-label-link" type="condition" conceptid="318448" conceptname="Second degree atrioventricular block">Wenckebach</span>), or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> (including <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>); <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> with block; <span class="product-label-link" type="condition" conceptid="4175473" conceptname="Atrioventricular dissociation">AV dissociation</span>; accelerated junctional (nodal) rhythm; unifocal or multiform ventricular premature contractions (especially <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">bigeminy</span> or <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">trigeminy</span>); <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>; and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. Digoxin produces PR prolongation and <span class="product-label-link" type="condition" conceptid="4095285" conceptname="ST segment depression">ST segment depression</span> which should not by themselves be considered <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. Cardiac toxicity can also occur at therapeutic doses in patients who have conditions which may alter their sensitivity to digoxin (see WARNINGS and PRECAUTIONS).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94404755-87c3-434e-84e8-93e042c45b7a"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Gastrointestinal</span></span></h3>
<p class="First">Digoxin may cause <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Rarely, the use of digoxin has been associated with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">intestinal ischemia</span>, and hemorrhagic <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the intestines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_448e9308-a7ae-4730-bfa4-62955f76b2eb"></a><a name="section-7.1.3"></a><p></p>
<h3><span class="Italics"><span class="Bold">CNS</span></span></h3>
<p class="First">Digoxin can produce <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (blurred or yellow vision), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and mental disturbances (such as <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97bee6ed-a9fc-4b17-a1a6-2e39ea0e8b0e"></a><a name="section-7.1.4"></a><p></p>
<h3><span class="Italics"><span class="Bold">Other</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> has been occasionally observed following the prolonged use of digoxin. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span> and other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been rarely observed.</p>
<p>Table 4 summarizes the incidence of those adverse experiences listed above for patients treated with LANOXIN Tablets or placebo from 2 randomized, double-blind, placebo-controlled withdrawal trials. Patients in these trials were also receiving diuretics with or without angiotensin-converting enzyme inhibitors. These patients had been stable on digoxin, and were randomized to digoxin or placebo. The results shown in Table 4 reflect the experience in patients following dosage titration with the use of serum digoxin concentrations and careful follow-up. These adverse experiences are consistent with results from a large, placebo-controlled mortality trial (DIG trial) wherein over half the patients were not receiving digoxin prior to enrollment.</p>
<a name="id_c4ea5aa3-43a4-4e19-9647-27debdce16c5"></a><table width="0.000">
<caption><span>Table 4. Adverse Experiences In 2 Parallel, Double-Blind, Placebo-Controlled Withdrawal Trials (Number of Patients Reporting)</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Adverse Experience</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Digoxin Patients</p>
<p>(nÂ =Â 123)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Placebo Patients</p>
<p>(nÂ =Â 125)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Cardiac</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4Â </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â VÂ entricular extrasystole</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Heart arrest</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Gastrointestinal</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">CNS</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â Mental disturbances</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Other</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5f71cc0-0ee0-45ae-b4a0-722182c47060"></a><a name="section-7.2"></a><p></p>
<h2>Infants and Children</h2>
<p class="First">The side effects of digoxin in infants and children differ from those seen in adults in several respects. Although digoxin may produce <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and CNS disturbances in young patients, these are rarely the initial symptoms of overdosage. Rather, the earliest and most frequent manifestation of excessive dosing with digoxin in infants and children is the appearance of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>. In children, the use of digoxin may produce any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. The most common are conduction disturbances or supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> (with or without block) and junctional (nodal) <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> are less common. <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> may be a sign of impending digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, especially in infants, even in the absence of first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> or alteration in cardiac conduction that develops in a child taking digoxin should be assumed to be caused by digoxin, until further evaluation proves otherwise.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ba3700aa-f3dc-4add-8580-f67869dc3a39"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1a5923e-fe6d-410b-ba0f-1f5593576527"></a><a name="section-8.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">The signs and symptoms of toxicity are generally similar to those described in the ADVERSE REACTIONS section but may be more frequent and can be more severe. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> become more frequent with levels above 2Â ng/mL. However, in deciding whether a patientâ€™s symptoms are due to digoxin, the clinical state together with serum electrolyte levels and thyroid function are important factors (see DOSAGE AND ADMINISTRATION).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf46c742-8058-43ab-9af1-55d702098544"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Adults</span></span></h3>
<p class="First">In adults without heart disease, clinical observation suggests that an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of digoxin of 10 to 15 mg was the dose resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of half of the patients. If more than 25Â mg of digoxin was ingested by an adult without heart disease, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or progressive toxicity responsive only to digoxin-binding Fab antibody fragments resulted. Cardiac manifestations are the most frequent and serious sign of both acute and chronic toxicity. Peak cardiac effects generally occur 3 to 6 hours following overdosage and may persist for the ensuing 24 hours or longer. <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin toxicity</span> may result in almost any type of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (see ADVERSE REACTIONS). Multiple rhythm disturbances in the same patient are common. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span> or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> due to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> is usually fatal.</p>
<p>Among the extra-cardiac manifestations, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) are very common (up to 80% incidence) and precede cardiac manifestations in approximately half of the patients in most literature reports. Neurologic manifestations (e.g. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, various CNS disturbances), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> are very common. Visual manifestations may also occur with aberration in color vision (predominance of yellow green) the most frequent. Neurological and visual symptoms may persist after other signs of toxicity have resolved. In chronic toxicity, non-specific extra-cardiac symptoms, such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, may predominate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_932cb1fa-f5c3-4340-b804-cab60b4786e1"></a><a name="section-8.1.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Children</span></span></h3>
<p class="First">In children aged 1 to 3 years without heart disease, clinical observation suggests that an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of digoxin of 6 to 10 mg was the dose resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in half of the patients. If more than 10 mg of digoxin was ingested by a child aged 1 to 3 years without heart disease, the outcome was uniformly fatal when Fab fragment treatment was not given. Most manifestations of toxicity in children occur during or shortly after the loading phase with digoxin. The same <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or combination of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> that occur in adults can occur in pediatrics. <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, and rapid <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> are seen less frequently in the pediatric population. Pediatric patients are more likely to present with an AV conduction disturbance or a <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>. Any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> or alteration in cardiac conduction that develops in a child taking digoxin should be assumed to be caused by digoxin, until further evaluation proves otherwise.</p>
<p>The frequent extracardiac manifestations similar to those seen in adults are gastrointestinal, CNS, and visual. However, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are not frequent in infants and small children.</p>
<p>In addition to the undesirable effects seen with recommended doses, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in older age groups and <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span> in infants, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> due to mesenteric artery <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and behavioral disturbances including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations have been reported in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bfea7b5-6de7-45c8-ad12-268b1409da84"></a><a name="section-8.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">In addition to cardiac monitoring, digoxin should be temporarily discontinued until the adverse reaction resolves and may be all that is required to treat the adverse reaction such as in asymptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or digoxin-related <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Every effort should also be made to correct factors that may contribute to the adverse reaction (such as <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, thyroid function, or concurrent medications) (see WARNINGS and PRECAUTIONS: Drug Interactions). Once the adverse reaction has resolved, therapy with digoxin may be reinstituted, following a careful reassessment of dose.</p>
<p>When the primary manifestation of digoxin overdosage is a <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, additional therapy may be needed. </p>
<p>If the rhythm disturbance is a symptomatic <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmia</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, consideration should be given to the reversal of toxicity with Digoxin Immune Fab (Ovine) [DIGIBIND<span class="Sup">Â®</span> or DIGIFAB<span class="Sup">Â®</span>] (see Massive Digitalis Overdosage subsection), the use of atropine, or the insertion of a temporary cardiac pacemaker. Digoxin Immune Fab (Ovine) is a specific antidote for digoxin and may be used to reverse potentially life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> due to digoxin overdosage.</p>
<p>If the rhythm disturbance is a <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, consideration should be given to the correction of electrolyte disorders, particularly if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (see Administration of Potassium subsection) or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> is present. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> may respond to lidocaine or phenytoin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3b20c58-c0f0-4583-98a5-f025ee77759e"></a><a name="section-8.2.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Administration of Potassium</span></span></h3>
<p class="First">Before administering potassium in digoxin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> for <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, the serum potassium must be known and every effort should be made to maintain the serum potassium concentration between 4 and 5.5Â mmol/L. Potassium salts should be avoided as they may be dangerous in patients who manifest <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> due to digoxin (unless primarily related to <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>) and in the setting of massive digitalis overdosage. Potassium is usually administered orally, but when correction of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> is urgent and the serum potassium concentration is low, potassium may be administered cautiously by the intravenous route. The electrocardiogram should be monitored for any evidence of potassium toxicity (e.g., peaking of T waves) and to observe the effect on the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68dc399c-d08d-4946-97d4-2b4046b8cb84"></a><a name="section-8.2.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Massive Digitalis Overdosage</span></span></h3>
<p class="First">Manifestations of life-threatening toxicity include <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, or progressive <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p>Digoxin Immune Fab (Ovine) should be used to reverse the toxic effects of ingestion of a massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. The decision to administer Digoxin Immune Fab (Ovine) to a patient who has ingested a massive dose of digoxin but who has not yet manifested life-threatening toxicity should depend on the likelihood that life-threatening toxicity will occur (see above).</p>
<p>Digoxin is not effectively removed from the body by dialysis due to its large extravascular volume of distribution. Patients with massive digitalis ingestion should receive large doses of activated charcoal to prevent absorption and bind digoxin in the gut during enteroenteric recirculation. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> may be indicated especially if ingestion has occurred within 30Â minutes of the patientâ€™s presentation at the hospital. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> should not be induced in patients who are obtunded. If a patient presents more than 2Â hours after ingestion or already has toxic manifestations, it may be unsafe to induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> because such maneuvers may induce an acute vagal episode that can worsen digitalis-related <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.</p>
<p>In cases where a large amount of digoxin has been ingested, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be present due to release of potassium from skeletal muscle. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> caused by massive <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> is best treated with Digoxin Immune Fab (Ovine); initial treatment with glucose and insulin may also be required if <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> itself is acutely life-threatening.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_96569a04-d3c9-469f-8fa1-2204ad53a0f4"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abfd6330-e427-43ee-becd-74a6c3615dad"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">Recommended dosages of digoxin may require considerable modification because of individual sensitivity of the patient to the drug, the presence of associated conditions, or the use of concurrent medications.</p>
<p>Parenteral administration of digoxin should be used only when the need for rapid digitalization is urgent or when the drug cannot be taken orally. Intramuscular injection can lead to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the injection site, thus intravenous administration is preferred. If the drug must be administered by the intramuscular route, it should be injected deep into the muscle followed by massage. No more than 200Â mcg (2Â mL) should be injected into a single site.</p>
<p>LANOXIN Injection Pediatric can be administered undiluted or diluted with a 4-fold or greater volume of Sterile Water for Injection, 0.9% Sodium Chloride Injection, or 5% Dextrose Injection. The use of less than a 4-fold volume of diluent could lead to precipitation of the digoxin. Immediate use of the diluted product is recommended.</p>
<p>If tuberculin syringes are used to measure very small doses, one must be aware of the problem of inadvertent overadministration of digoxin. The syringe should <span class="Italics">not</span> be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with the parenteral solution after its contents are expelled into an indwelling vascular catheter.</p>
<p>Slow infusion of LANOXIN Injection Pediatric is preferable to bolus administration. Rapid infusion of digitalis glycosides has been shown to cause systemic and coronary arteriolar constriction, which may be clinically undesirable. Caution is thus advised and LANOXIN Injection Pediatric should probably be administered over a period of 5Â minutes or longer. Mixing of LANOXIN Injection Pediatric with other drugs in the same container or simultaneous administration in the same intravenous line is not recommended.</p>
<p>In selecting a dose of digoxin, the following factors must be considered:</p>
<ol>
<li>The body weight of the patient. Doses should be calculated based upon lean (i.e., ideal) body weight.</li>
<li>The patientâ€™s renal function, preferably evaluated on the basis of estimated creatinine clearance.</li>
<li>The patientâ€™s age. Infants and children require different doses of digoxin than adults. Also, advanced age may be indicative of diminished renal function even in patients with normal serum creatinine concentration (i.e., below 1.5Â mg/dL).</li>
<li>Concomitant disease states, concurrent medications, or other factors likely to alter the pharmacokinetic or pharmacodynamic profile of digoxin (see PRECAUTIONS).</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c183ccc6-d3de-448e-9b72-5aa53fe015a5"></a><a name="section-9.2"></a><p></p>
<h2>Serum Digoxin Concentrations</h2>
<p class="First">In general, the dose of digoxin used should be determined on clinical grounds. However, measurement of serum digoxin concentrations can be helpful to the clinician in determining the adequacy of digoxin therapy and in assigning certain probabilities to the likelihood of digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. About two-thirds of adults considered adequately digitalized (without evidence of toxicity) have serum digoxin concentrations ranging from 0.8 to 2.0Â ng/mL. However, digoxin may produce clinical benefits even at serum concentrations below this range. About two-thirds of adult patients with clinical toxicity have serum digoxin concentrations greater than 2.0Â ng/mL. However, since one-third of patients with clinical toxicity have concentrations less than 2.0Â ng/mL, values below 2.0Â ng/mL do not rule out the possibility that a certain sign or symptom is related to digoxin therapy. Rarely, there are patients who are unable to tolerate digoxin at serum concentrations below 0.8Â ng/mL. Consequently, the serum concentration of digoxin should always be interpreted in the overall clinical context, and an isolated measurement should not be used alone as the basis for increasing or decreasing the dose of the drug.</p>
<p>To allow adequate time for equilibration of digoxin between serum and tissue, sampling of serum concentrations should be done just before the next scheduled dose of the drug. If this is not possible, sampling should be done at least 6 to 8Â hours after the last dose, regardless of the route of administration or the formulation used. On a once-daily dosing schedule, the concentration of digoxin will be 10% to 25% lower when sampled at 24Â versus 8Â hours, depending upon the patientâ€™s renal function. On a twice-daily dosing schedule, there will be only minor differences in serum digoxin concentrations whether sampling is done at 8 or 12Â hours after a dose.</p>
<p>If a discrepancy exists between the reported serum concentration and the observed clinical response, the clinician should consider the following possibilities:</p>
<ol>
<li>Analytical problems in the assay procedure.</li>
<li>Inappropriate serum sampling time.</li>
<li>Administration of a digitalis glycoside other than digoxin.</li>
<li>Conditions (described in WARNINGS and PRECAUTIONS) causing an alteration in the sensitivity of the patient to digoxin.</li>
<li>Serum digoxin concentration may decrease acutely during periods of exercise without any associated change in clinical efficacy due to increased binding of digoxin to skeletal muscle.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26b7a729-39e9-4cae-b916-b2ef9d3bbd9c"></a><a name="section-9.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18f55b34-bcb3-460a-8280-339381e72ad9"></a><a name="section-9.3.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Adults</span></span></h3>
<p class="First">See the full prescribing information for LANOXIN Injection for specific recommendations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aab94706-bd8e-4d86-9c27-93d686535d44"></a><a name="section-9.3.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Infants and Children</span></span></h3>
<p class="First">In general, divided daily dosing is recommended for infants and young children (under ageÂ 10). In the newborn period, renal clearance of digoxin is diminished and suitable dosage adjustments must be observed. This is especially pronounced in the premature infant. Beyond the immediate newborn period, children generally require proportionally larger doses than adults on the basis of body weight or body surface area. Children over 10Â years of age require adult dosages in proportion to their body weight. Some researchers have suggested that infants and young children tolerate slightly higher serum concentrations than do adults.</p>
<p>Digitalization may be accomplished by either of two general approaches that vary in dosage and frequency of administration, but reach the same endpoint in terms of total amount of digoxin accumulated in the body.</p>
<ol>
<li>If rapid digitalization is considered medically appropriate, it may be achieved by administering a loading dose based upon projected peak digoxin body stores. Maintenance dose can be calculated as a percentage of the loading dose.</li>
<li>More gradual digitalization may be obtained by beginning an appropriate maintenance dose, thus allowing digoxin body stores to accumulate slowly. Steady-state serum digoxin concentrations will be achieved in approximately five half-lives of the drug for the individual patient. Depending upon the patientâ€™s renal function, this will take between 1 and 3Â weeks.</li>
</ol>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8155b140-cb0b-4320-977e-bc0d4b4f4272"></a><a name="section-9.3.2.1"></a><p></p>
<h4><span class="Italics"><span class="Bold">Rapid Digitalization With a Loading Dose</span></span></h4>
<p class="First">LANOXIN Injection Pediatric can be used to achieve rapid digitalization, with conversion to an oral formulation of LANOXIN for maintenance therapy. If patients are switched from intravenous to oral digoxin formulations, allowances must be made for differences in bioavailability when calculating maintenance dosages (see Table 1 in CLINICAL PHARMACOLOGY: Pharmacokinetics and dosing Table 5).</p>
<p>Intramuscular injection of digoxin is extremely painful and offers no advantages unless other routes of administration are contraindicated.</p>
<p>Peak digoxin body stores of 8 to 12Â  mcg/kg should provide therapeutic effect with minimum risk of toxicity in most patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and normal sinus rhythm. Because of altered digoxin distribution and elimination, projected peak body stores for patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> should be conservative (i.e., 6 to 10Â  mcg/kg) (see PRECAUTIONS).</p>
<p>Digitalizing and daily maintenance doses for each age group are given in Table 5 and should provide therapeutic effect with minimum risk of toxicity in most patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and normal sinus rhythm. These recommendations assume the presence of normal renal function.</p>
<p>The loading dose should be administered in several portions, with roughly half the total given as the first dose. Additional fractions of this planned total dose may be given at 4- to 8-hour intervals, <span class="Bold">with careful assessment of clinical response before each additional dose.</span> If the patientâ€™s clinical response necessitates a change from the calculated loading dose of digoxin, then calculation of the maintenance dose should be based upon the amount actually given.</p>
<a name="id_0fbd34b2-9b44-4d19-b2a8-9c91beb19d26"></a><table width="0.000">
<caption><span>Table 5. Usual Digitalizing and Maintenance Dosages for LANOXIN<span class="Sup">Â®</span>Injection Pediatric in Children With Normal Renal Function Based on Lean Body Weight</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Age</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">IV Digitalizing<span class="Sup">a</span> Dose (mcg/kg)</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Daily</span> IV Maintenance Dose<span class="Sup">b</span></p>
<p>(mcg/kg)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Premature</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15 to 25</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20% to 30% of the IV digitalizing dose<span class="Sup">c</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Full-Term</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20 to 30</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">1 to 24 Months</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">30 to 50</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">2 to 5 Years</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">25 to 35</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">25% to 35% of the IV digitalizing dose<span class="Sup">c</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">5 to 10 Years</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15 to 30</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Over 10 Years</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">8 to 12</p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> IV digitalizing doses are 80% of oral digitalizing doses.</p>
<p><span class="Sup">b</span> Divided daily dosing is recommended for children under 10Â years of age.</p>
<p><span class="Sup">c</span> Projected or actual digitalizing dose providing clinical response.<br></p>
<p>In children with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, digoxin dosing must be carefully titrated based on clinical response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43056848-0d2f-4cc8-ba86-9fa66bb46557"></a><a name="section-9.3.2.2"></a><p></p>
<h4><span class="Italics"><span class="Bold">Gradual Digitalization With A Maintenance Dose</span></span></h4>
<p class="First">More gradual digitalization can also be accomplished by beginning an appropriate maintenance dose. The range of percentages provided in Table 5 can be used in calculating this dose for patients with normal renal function.</p>
<p><span class="Bold">It cannot be overemphasized that these pediatric dosage guidelines are based upon average patient response and substantial individual variation can be expected. Accordingly, ultimate dosage selection must be based upon clinical assessment of the patient.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_500e36e2-fd36-4cfd-af84-267800d42704"></a><a name="section-9.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First">Peak digoxin body stores larger than the 8 to 12Â mcg/kg required for most patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and normal sinus rhythm have been used for control of ventricular rate in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. Doses of digoxin used for the treatment of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> should be titrated to the minimum dose that achieves the desired ventricular rate control without causing undesirable side effects. Data are not available to establish the appropriate resting or exercise target rates that should be achieved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8316a480-ef87-401c-bf54-a7a5e2dc7853"></a><a name="section-9.5"></a><p></p>
<h2>Dosage Adjustment When Changing Preparations</h2>
<p class="First">The differences in bioavailability between injectable LANOXIN or LANOXIN Tablets must be considered when changing patients from one dosage form to another.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_3945720c-1f8a-4bc1-8611-97985c18c899"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">LANOXIN (digoxin) Injection Pediatric, 100Â mcg (0.1Â mg) in 1Â mL; box of 10 ampuls (NDCÂ 24987-262-10). </p>
<p><span class="Bold">Store at 25Â°C (77Â°F); excursions permitted to 15 to 30Â°C (59 to 86Â°F) [see USP Controlled Room Temperature] and protect from light.</span><br><br></p>
<p>LANOXIN and DIGIBIND are registered trademarks of GlaxoSmithKline</p>
<p>DIGIFAB is a registered trademark of BTG International Inc. </p>
<p><img alt="Covis" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=58678fd6-afe3-4a4c-a37f-356444194cd6&amp;name=5de543bc-1234-4760-b78b-b8f0258aa45c-02.jpg"></p>
<p>Distributed by<br>Covis Pharmaceuticals, Inc.<br>Cary, NC 27511</p>
<p>Manufactured by <br>DSM Pharmaceuticals, Inc.<br>Greenville, NC 27834 </p>
<p>Â©2012, Covis Pharmaceuticals, Inc. All rights reserved.</p>
<p>May 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_74e89f4b-40f8-4d3f-aa51-bc4cdd16a929"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Lanoxin Injection Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=58678fd6-afe3-4a4c-a37f-356444194cd6&amp;name=5de543bc-1234-4760-b78b-b8f0258aa45c-03.jpg"></div>
<p class="First"><span class="Bold">NDC 24987-262-10</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10 ampuls 1 mL each</p>
<p><span class="Bold">LANOXIN <span class="Sup">Â®</span> (digoxin) Injection</span></p>
<p><span class="Bold">Pediatric</span></p>
<p><span class="Bold">100 mcg (0.1 mg) in 1 mL </span></p>
<p>A sterile solution for intravenous or intramuscular injection. Dilution not required.Â In a vehicle of 40% propylene glycol and 10% alcohol. Sodium phosphate 0.17%. Citric acid anhydrous 0.08%.Â </p>
<p>See prescribing information for dosage information.</p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15 to 30Â°C (59 to 86Â°F) <br>[see USP Controlled Room Temperature] and protect from light. </p>
<p><span class="Bold">R<span class="Sub">x</span> only</span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â C O V I S</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LANOXINÂ 		
					</strong><br><span class="contentTableReg">digoxin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24987-262</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIGOXIN</strong> (DIGOXIN) </td>
<td class="formItem">DIGOXIN</td>
<td class="formItem">100Â ug Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24987-262-10</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA009330</td>
<td class="formItem">01/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Covis Pharmaceuticals Inc
							(969968986)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5de543bc-1234-4760-b78b-b8f0258aa45c</div>
<div>Set id: 58678fd6-afe3-4a4c-a37f-356444194cd6</div>
<div>Version: 2</div>
<div>Effective Time: 20130114</div>
</div>
</div>Â <div class="DistributorName">Covis Pharmaceuticals Inc</div></p>
</body></html>
